Project Summary Pediatric cardiomyopathies encompass a heterogeneous group of disorders including dilated, hypertrophic, and less commonly, restrictive cardiomyopathies. Emerging experimental evidence and epidemiologic data suggest that the pediatric heart failure population is distinctly different from adult patients The most common cause of heart failure and reason for cardiac transplantation in children older than 1 year is dilated cardiomyopathy (DCAmong these etiologies, pediatric dilated cardiomyopathy (DCM) has an estimated 40% five year transplant-free survival and remains the most common diagnosis leading to heart transplant in children greater than 1 year of age. The central hypothesis is that circulating microRNAs (miRs) will be useful biomarkers for risk stratification, will correlate with outcomes and may represent novel therapeutic targets in children with DCM. The aims of this study are: 1) Determine the profile of circulating miRs in a cohort of children with DCM and acute systolic heart failure. The circulating miR expression patterns will then be stratified based on reaching a primary end-point by 1 year defined as:  death or transplantation,  recovery (normalization of ventricular size and function) or  stable DCM (persistent ventricular dilation or dysfunction); 2) Define the miR profile in a separate cohort of children with chronic, stable DCM to determine if those patients with stable DCM who progress to death/transplant within 1 year will be similar to the profile of the Aim 1 cohort of children with acute heart failure who also progress to death/transplant; and 3) Analyze the expression of circulating and heart tissue miRs in pediatric controls (non-failing donors whose heart could not be placed [NF]) and pediatric DCM patients. The results of this study could improve clinicians prognostic? assessment at diagnosis of DCM in children, improve decision-making regarding listing children for heart transplant as opposed to identifying those who are expected to recover ventricular function, and could provide insight into cellular mechanisms of disease and define novel targets for future treatment of DCM in children.
|Effective start/end date||2/17/18 → 1/31/22|
- National Institutes of Health: $795,301.00
- National Institutes of Health: $47,571.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.